Funder
Rehabilitation Research and Development Service
Bristol-Myers Squibb
Genentech
U.S. Department of Veterans Affairs
Novartis
Subject
Neurology (clinical),Neurology,General Medicine
Reference16 articles.
1. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies;Achiron;Ther Adv Neurol Disord,2021
2. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy;Apostolidis;Nat. Med.,2021
3. Efficacy and safety of the mrna-1273 sars-cov-2 vaccine;Baden;N. Engl. J. Med.,2021
4. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study;Barda;The Lancet,2021
5. Impact of disease-modifying treatments of multiple sclerosis on anti–sars-cov-2 antibodies: an observational study;Bigaut;Neurol Neuroimmunol Neuroinflamm,2021
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献